SCHEMBL25819126

SCHEMBL25819126

Cc1ccc(-c2ccc(O)cc2)c(OCc2ccccc2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.47
LMNA P02545 2/20 0.46
CYP1A2 P05177 1/20 0.46
PTGS1 P23219 1/20 0.46
SLC6A2 P23975 1/20 0.46
CYP2C19 P33261 1/20 0.46
PTGS2 P35354 1/20 0.46
SLC6A3 Q01959 1/20 0.46
HIF1A Q16665 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
MGAM O43451 3/20 0.45
GAA P10253 3/20 0.45
SI P14410 3/20 0.45
MGAM2 Q2M2H8 3/20 0.45
CNR1 P21554 7/20 0.44
SQOR Q9Y6N5 1/20 0.43
MAPT P10636 2/20 0.42
NPSR1 Q6W5P4 2/20 0.42
MAPK1 P28482 2/20 0.41
ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26043793 0.87 MAPT (0.47) L3MBTL1GAACNR1SQORMAPT
SCHEMBL26044686 0.87 MEN1 (0.48) L3MBTL1LMNACYP1A2CYP2C19GAA
SCHEMBL26043794 0.87 L3MBTL1 (0.46) L3MBTL1CNR1SQORTSHR
SCHEMBL25819100 0.85 L3MBTL1 (0.43) L3MBTL1LMNACNR1SQORMAPT
SCHEMBL24207230 0.84 LMNA (0.47) L3MBTL1LMNACYP1A2PTGS1SLC6A2
SCHEMBL25819197 0.81 L3MBTL1 (0.44) L3MBTL1GAACNR1SQORMAPT
SCHEMBL25819597 0.80 L3MBTL1 (0.42) L3MBTL1CNR1SQORTSHR
SCHEMBL25819527 0.80 L3MBTL1 (0.43) L3MBTL1LMNACYP1A2PTGS1SLC6A2
SCHEMBL25935014 0.79 GABRG2 (0.49) L3MBTL1CNR1SQOR
SCHEMBL31105721 0.77 L3MBTL1 (0.47) L3MBTL1CNR1SQORMAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers UPPTHERA, INC. (KR) 2024-02-27 US disclosed
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND PLK1, BUB1B, BUB1 L3MBTL1 964/4885LMNA 2201/4885CYP1A2 4728/4885
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers PLK1, BUB1B, BUB1 L3MBTL1 2040/4885LMNA 1899/4885CYP1A2 3880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.